Chugai Signs License Agreement With Rani Therapeutics for Oral Biologics Development

Reuters

2025/10/20

Chugai Signs License Agreement With Rani <a href="https://laohu8.com/S/LENZ">Therapeutics</a> for Oral Biologics Development

Chugai Pharmaceutical Co., Ltd. has announced a license agreement with Rani Therapeutics for the development and commercialization of an oral formulation leveraging RaniPill® technology. Under the terms of the agreement, Chugai will make an upfront payment of $10 million to Rani Therapeutics, with the potential for up to $75 million in technology transfer and development milestone payments, and up to $100 million in sales-based milestone payments, contingent on the commercial success of the molecule. Additional single digit royalties on sales are also included if commercialization is successful. Chugai has the option to extend its rights to five additional targets under similar terms, potentially bringing the total deal value to over $1 billion if fully exercised. This agreement is not expected to impact Chugai's consolidated financial forecast for the fiscal year ending December 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2576004464"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576004464\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576004464?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 07:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576004464","market":"nz","top_or_hot":-1,"title":"Chugai Signs License Agreement With Rani Therapeutics for Oral Biologics Development","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Chugai Signs License Agreement With Rani <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for Oral Biologics Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CHGCF\">Chugai Pharmaceutical Co., Ltd.</a> has announced a license agreement with Rani Therapeutics for the development and commercialization of an oral formulation leveraging RaniPill® technology. Under the terms of the agreement, Chugai will make an upfront payment of $10 million to Rani Therapeutics, with the potential for up to $75 million in technology transfer and development milestone payments, and up to $100 million in sales-based milestone payments, contingent on the commercial success of the molecule. Additional single digit royalties on sales are also included if commercialization is successful. Chugai has the option to extend its rights to five additional targets under similar terms, potentially bringing the total deal value to over $1 billion if fully exercised. This agreement is not expected to impact Chugai's consolidated financial forecast for the fiscal year ending December 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chugai Signs License Agreement With Rani Therapeutics for Oral Biologics Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChugai Signs License Agreement With Rani Therapeutics for Oral Biologics Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-20 07:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Chugai Signs License Agreement With Rani <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for Oral Biologics Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CHGCF\">Chugai Pharmaceutical Co., Ltd.</a> has announced a license agreement with Rani Therapeutics for the development and commercialization of an oral formulation leveraging RaniPill® technology. Under the terms of the agreement, Chugai will make an upfront payment of $10 million to Rani Therapeutics, with the potential for up to $75 million in technology transfer and development milestone payments, and up to $100 million in sales-based milestone payments, contingent on the commercial success of the molecule. Additional single digit royalties on sales are also included if commercialization is successful. Chugai has the option to extend its rights to five additional targets under similar terms, potentially bringing the total deal value to over $1 billion if fully exercised. This agreement is not expected to impact Chugai's consolidated financial forecast for the fiscal year ending December 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251019:nNDLbr50Ry:1","article_id":"2576004464","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576004464","pubTimestamp":1760916838,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Chugai Pharmaceutical Co., Ltd. has announced a license agreement with Rani Therapeutics for the development and commercialization of an oral formulation leveraging RaniPill technology. Under the terms of the agreement, Chugai will make an upfront payment of $10 million to Rani Therapeutics, with the potential for up to $75 million in technology transfer and development milestone payments, and up to $100 million in sales-based milestone payments, contingent on the commercial success of the molecule. Additional single digit royalties on sales are also included if commercialization is successful. Chugai has the option to extend its rights to five additional targets under similar terms, potentially bringing the total deal value to over $1 billion if fully exercised. This agreement is not expected to impact Chugai's consolidated financial forecast for the fiscal year ending December 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","RANI":"Rani Therapeutics Holdings","BK4007":"制药"},"translate_title":"中外制药与Rani Therapeutics签署口服生物制剂开发许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RANI":0.9},"content_text":"Chugai Signs License Agreement With Rani Therapeutics for Oral Biologics Development\n    \n\nChugai Pharmaceutical Co., Ltd. has announced a license agreement with Rani Therapeutics for the development and commercialization of an oral formulation leveraging RaniPill® technology. Under the terms of the agreement, Chugai will make an upfront payment of $10 million to Rani Therapeutics, with the potential for up to $75 million in technology transfer and development milestone payments, and up to $100 million in sales-based milestone payments, contingent on the commercial success of the molecule. Additional single digit royalties on sales are also included if commercialization is successful. Chugai has the option to extend its rights to five additional targets under similar terms, potentially bringing the total deal value to over $1 billion if fully exercised. This agreement is not expected to impact Chugai's consolidated financial forecast for the fiscal year ending December 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}